Parkinson's Disease (PD) Models
Creative Bioarray provides Parkinson’s disease animal models for preclinical drug discovery, efficacy evaluation, and translational neuroscience research. Our platform includes neurotoxin-induced, and α-synuclein-based models for dopaminergic neurodegeneration, neuroinflammation, mitochondrial dysfunction, and disease-modifying therapeutic development.
Background of Parkinson's Disease (PD)
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the selective degeneration of dopaminergic neurons in the substantia nigra pars compacta and progressive depletion of striatal dopamine levels. Currently, PD is one of the most common neurodegenerative disorders worldwide, affecting more than 10 million people globally.
The pathological hallmarks of PD include α-synuclein aggregation, Lewy body formation, mitochondrial dysfunction, oxidative stress, neuroinflammation, and progressive neuronal loss. These pathological changes disrupt basal ganglia circuitry and result in motor symptoms, including bradykinesia, resting tremor, rigidity, and postural instability, as well as non-motor symptoms such as cognitive impairment, sleep disturbances, autonomic dysfunction, anxiety, and depression.
Sustained neuroinflammation, driven by microglial and astrocytic activation, contributes to chronic inflammatory signaling and progressive neurodegeneration. Abnormal α-synuclein aggregation further exacerbates mitochondrial dysfunction, oxidative stress, and synaptic impairment, ultimately forming a self-propagating neurodegenerative cascade.
Fig. 1. Pathogenesis of Parkinson's disease (Aryal S, Skinner T, et al. 2020).
Although current treatments can temporarily relieve symptoms, no approved disease-modifying therapies are available to halt or reverse dopaminergic neuron loss. Therefore, physiologically relevant animal models of Parkinson's disease remain essential for mechanistic studies, target validation, biomarker discovery, efficacy evaluation, and translational drug development.
Creative Bioarray's Parkinson's Disease (PD) Models
Neurotoxin-Induced Parkinson's Disease (PD) Models
MPTP-Induced Parkinson's Disease (PD) Model
MPTP is converted to MPP+ that inhibits mitochondrial complex I and causes selective destruction of dopaminergic neurones of substantia nigra. MPTP-induced mice are characterized by rapid dopamine depletion, motor dysfunction and nigrostriatal degeneration and are extensively employed for studying neuroprotection and evaluating anti-PD drugs.
6-OHDA-Induced Parkinson's Disease (PD) Model
6-Hydroxydopamine (6-OHDA) is injected into the substantia nigra (SN), medial forebrain bundle (MFB), or striatum to selectively induce degeneration of nigrostriatal dopaminergic neurons. MFB and SN injections cause rapid and extensive dopaminergic neuronal loss (often >90% in MFB lesions) within days, representing advanced-stage Parkinsonian pathology. In contrast, striatal injection induces progressive retrograde degeneration over 1–3 weeks with partial neuronal preservation, making it more suitable for neuroprotection and neurorestoration studies. The unilateral 6-OHDA lesion model produces robust and reproducible motor asymmetry, supporting behavioural pharmacology and evaluation of antiparkinsonian therapies.
α-Synuclein-Based Parkinson's Disease (PD) Models
AAV-α-Synuclein Overexpression Model
AAV-mediated overexpression of α-synuclein produces progressive synucleinopathy, neuroinflammation and dopaminergic neurone degeneration. They are frequently utilized in the development of gene therapies and for the evaluation of anti-α-synuclein therapeutics.
α-Synuclein Preformed Fibril (PFF) Model
PFF models induce seeded α-synuclein aggregation and prion-like propagation across neural circuits. These systems are particularly useful for studying disease progression, synuclein spreading, and disease-modifying treatment options.
Model Comparison Overview
| Model Type | Model | Induction Method | Disease Features | Primary Application |
| Neurotoxin | MPTP | Systemic (i.p.) neurotoxin injection | Bilateral dopamine depletion, motor deficits | Drug screening |
| Neurotoxin | 6-OHDA | Stereotaxic neurotoxin injection | Unilateral lesion, behavioral asymmetry | Behavioral pharmacology |
| α-Synuclein | AAV-α-syn | Viral overexpression | Progressive synucleinopathy | α-Synuclein-targeted therapeutics (gene therapy, ASO, immunotherapy) |
| α-Synuclein | PFF | Protein fibril injection | Pathological propagation | Disease progression & synuclein-targeted therapeutics |
Endpoints
Creative Bioarray provides integrated multi-dimensional endpoint analysis for comprehensive evaluation of Parkinson's disease (PD) progression, neurodegeneration, therapeutic efficacy, and translational pharmacology.
Behavioral Assessments
- Rotarod test
- Open field test
- Cylinder test
- Pole test
- Apomorphine-induced rotation
Histopathology & Immunostaining
- Tyrosine hydroxylase (TH) staining
- α-Synuclein / p-S129 α-synuclein staining
- NeuN staining (neuronal integrity)
- Iba1 / GFAP staining (neuroinflammation)
Neurochemical & Functional Analysis
- Dopamine / DOPAC / HVA quantification
- Oxidative stress markers
- Mitochondrial function assays
Molecular Mechanism Analysis
- Western blot / qPCR
- ELISA
- Neuroinflammatory pathway analysis
- Protein aggregation analysis
Why Choose Creative Bioarray for Parkinson's Disease Studies
Broad Model Coverage
Comprehensive neurotoxin-induced, α-synuclein-based, and genetic Parkinson's disease models for diverse neuroscience research applications.
Human-Relevant Study Design
Our model portfolio spans the full spectrum of PD pathology - from dopaminergic neurodegeneration and mitochondrial dysfunction (neurotoxin models) to α-synuclein aggregation and propagation (PFF) - allowing researchers to select the model best matched to their specific pathological question
Integrated Multi-Level Analysis
Combined behavioral, histopathological, neurochemical, and molecular endpoint analysis for comprehensive efficacy evaluation.
Flexible CRO Study Design
Customized study design for efficacy studies, mechanism investigation, biomarker development, and translational pharmacology research.
FAQ
What is the most commonly used Parkinson's disease animal model?
The MPTP-induced Parkinson's disease model is one of the most widely used preclinical models because it reliably induces dopaminergic neuron degeneration, dopamine depletion, and motor dysfunction. MPTP is primarily used in mice and non-human primates due to species-specific metabolic sensitivity, while rat studies typically employ the 6-OHDA model instead.
What are the differences between MPTP and 6-OHDA models?
MPTP models primarily induce systemic mitochondrial dysfunction and bilateral dopaminergic degeneration, whereas 6-OHDA models generate localized unilateral lesions with pronounced motor asymmetry suitable for behavioral studies.
Which Parkinson's disease model is suitable for α-synuclein aggregation studies?
α-Synuclein overexpression and PFF models are widely used for investigating protein aggregation, propagation, and synuclein-targeted therapeutics.
What are common endpoints in Parkinson's disease efficacy studies?
Typical endpoints depend on the model selected, and include behavioral analysis, TH-positive neuron quantification, dopamine measurement, neuroinflammatory biomarkers, and mitochondrial function analysis for neurotoxin-induced models, while α-synuclein pathology assessment (including p-S129 staining and aggregate quantification) is primarily applied to α-synuclein PFF models.
Contact Us
Creative Bioarray provides customized Parkinson's disease CRO services for preclinical drug discovery, efficacy evaluation, mechanism investigation, and translational neuroscience research. Our scientific team supports model selection, study design, behavioral pharmacology, biomarker analysis, and integrated in vivo efficacy studies.
Contact us to discuss your Parkinson's disease animal model study.
Reference
- Aryal S, Skinner T, et al. The Pathology of Parkinson's Disease and Potential Benefit of Dietary Polyphenols. Molecules. 2020; 25(19):4382
Explore Other Options
